Beijing Biotech

This study tests a new treatment called EB-NK-301 for adults with advanced solid tumors that have stopped responding to standard therapies. EB-NK-301 uses specially engineered immune cells (CAR NK cells) to target a protein called TROP2 on cancer cells. The main goals are to chec…

This study tests a new approach using a patient's own immune cells, engineered to attack two cancer targets at once, for adults with advanced solid tumors that have not responded to standard treatments. Each participant's cancer is first tested to find the best two targets, then …

This study tests a new treatment using specially engineered natural killer (NK) cells to attack cancer cells in people with ovarian, peritoneal, or fallopian tube cancer that has come back or not responded to standard treatments. The therapy is personalized based on the specific …

This study tests a new treatment using specially engineered natural killer (NK) cells to fight mesothelioma, a cancer that lines the lungs or abdomen. The cells are designed to target two markers on the tumor and are given directly into the chest or belly. The trial involves 36 a…

This study tests a new treatment called EB-DUALNK for adults with ovarian cancer that has come back or not responded to standard therapies. The treatment uses specially engineered natural killer (NK) cells designed to target two cancer-related markers at once. Participants first …

This early-stage study tests a new treatment using specially engineered immune cells (CAR-NK cells) to attack cancer cells in adults with thymoma or thymic carcinoma that has come back or not responded to standard therapy. About 36 participants will receive one of three types of …

This study tests a new treatment made from donor immune cells (CAR-NK cells) designed to target two proteins on kidney cancer cells. It is for adults with advanced clear cell renal cell carcinoma that has worsened after standard treatments. The goal is to see if this therapy is s…

This early-stage trial tests a personalized cell therapy for adults with severe lupus that hasn't responded to standard treatments. Participants receive a single infusion of their own immune cells, re-engineered to target and destroy the faulty cells driving their disease. The st…

This study tests a new treatment using specially designed immune cells (CAR-NK cells) that target two markers on small cell lung cancer cells. The goal is to find a safe dose and see if these cells can shrink tumors in adults whose cancer has returned or not responded to standard…

This study tests a new treatment using specially designed immune cells (CAR-NK cells) that target specific markers on breast cancer cells. It is for people with advanced or metastatic breast cancer, including HER2-positive and triple-negative types, who have tried other treatment…

This study tests a new treatment for people with advanced bladder cancer that has not responded to standard therapies. The treatment uses specially engineered immune cells (CAR-NK cells) from a healthy donor to target and kill cancer cells. Up to 42 adults will receive the cells …

This study tests a new treatment using specially designed immune cells (CAR-NK cells) that target two proteins on neuroblastoma cells. It is for children and young adults aged 1 to 21 whose cancer has returned or not responded to standard treatments. The goal is to find a safe do…

This study tests a new type of CAR-T cell therapy that targets two different markers on cancer cells at once. It is for adults with blood cancers like leukemia, lymphoma, or myeloma that have come back or not responded to other treatments. The goal is to see if this dual-target a…

This study tests a new treatment using specially engineered natural killer (NK) cells that target two cancer markers (MSLN and MUC1, or CLDN18.2 and MUC1) in patients with advanced pancreatic cancer that cannot be removed by surgery. The goal is to find a safe dose and see if the…

This study is testing a new treatment for people with advanced breast cancer that has not responded to standard therapies. The treatment uses specially designed immune cells (CAR-NK cells) that are tailored to attack specific markers on each person's tumor. The goal is to see if …

This early-phase study tests whether specially engineered immune cells from healthy donors (CAR-NK cells) can safely attack advanced solid tumors. Participants' tumor markers are first identified through blood or tissue tests, then matched to a single- or dual-target cell product…

This study tests a new treatment for adults with advanced liver cancer that has stopped responding to standard therapies. The treatment uses specially engineered immune cells (CAR-NK cells) from a healthy donor that are designed to target and kill cancer cells. The study will fir…

This early-stage trial tests a new treatment made from donor immune cells (CAR-NK cells) designed to find and attack colorectal cancer cells. About 48 adults with advanced or metastatic colorectal cancer that has stopped responding to standard treatments will receive these cells.…

This study tests a new treatment for advanced stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. The treatment uses specially engineered immune cells (CAR-NK cells) from donated cord blood that target two proteins on cancer cells. Up to 3…

This early-phase study tests a new treatment for adults with glioblastoma or high-grade glioma that has come back after standard therapy. The treatment uses specially engineered natural killer (NK) cells designed to target two different markers on tumor cells at once, which may h…

This study tests a new treatment for people with advanced non-small cell lung cancer that has not responded to standard therapies. Participants receive specially designed natural killer (NK) immune cells that target two cancer markers at once. The goal is to see if this approach …

This early-phase trial tests a new treatment for adults with glioblastoma or other high-grade gliomas that have come back after standard therapy. The treatment uses specially engineered immune cells (CAR-NK cells) that are designed to target two different markers on tumor cells a…